losartan has been researched along with Arrhythmias, Cardiac in 24 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "EXP3174, but not losartan nor captopril, reduced the incidence of lethal ischemic ventricular arrhythmia in this preparation." | 7.70 | EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. ( Gould, RJ; Grossman, W; Kusma, SE; Lynch, JJ; Painter, CA; Stump, GL; Thomas, JM; Wallace, AA, 1999) |
| "To assess the efficacy of losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphe nyl-4-yl)methyl]imidazole, potassium salt), an angiotensin II receptor antagonist, on acute myocardial ischemia, 36 four-month-old spontaneously hypertensive rats were used." | 7.69 | Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats. ( Ding, YA; Lee, YM; Peng, YY; Yen, MH, 1997) |
| "To produce arrhythmia, the left main coronary artery was occluded for 7 min, followed by 7 min of reperfusion and to produce necrosis, the the left main coronary artery was occluded for 30 min, followed by 120 min of reperfusion." | 5.31 | Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats. ( Acet, A; Birincioglu, M; Ozer, MK; Sahna, E, 2002) |
| "There is increasing evidence that angiotensin II (Ang II) is associated with the occurrence of ventricular arrhythmias." | 3.74 | Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor. ( Dong, F; Sheng, JW; Shi, CX; Wang, YH; Xu, YF, 2008) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "A previous study by our group showed that 10 weeks of pretreatment with losartan reduced myocardial infarct size and arrhythmias in a rat model of ischaemia-reperfusion." | 3.71 | Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor. ( Browne, AE; Chatterjee, K; Lee, RJ; Parmley, WW; Sievers, RE; Sun, Y; Zhu, B, 2001) |
| " Losartan increased the threshold for ventricular fibrillation (p=0." | 3.71 | The renin-angiotensin system does not contribute to the endothelial dysfunction and increased infarct size in rats exposed to second hand smoke. ( Browne, AE; Chair, K; Chatterjee, K; Glantz, SA; Hillman, RT; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ, 2002) |
| "EXP3174, but not losartan nor captopril, reduced the incidence of lethal ischemic ventricular arrhythmia in this preparation." | 3.70 | EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. ( Gould, RJ; Grossman, W; Kusma, SE; Lynch, JJ; Painter, CA; Stump, GL; Thomas, JM; Wallace, AA, 1999) |
| "To assess the efficacy of losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphe nyl-4-yl)methyl]imidazole, potassium salt), an angiotensin II receptor antagonist, on acute myocardial ischemia, 36 four-month-old spontaneously hypertensive rats were used." | 3.69 | Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats. ( Ding, YA; Lee, YM; Peng, YY; Yen, MH, 1997) |
| "The contribution of arrhythmias is unclear." | 1.48 | Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome. ( Crosson, JE; Czosek, RJ; Lacro, RV; Love, BA; Mah, DY; McCrindle, BW; Muiño-Mosquera, L; Olson, AK; Pilcher, TA; Shah, MJ; Sleeper, LA; Tierney, ESS; Wechsler, SB; Young, LT, 2018) |
| "Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart." | 1.36 | Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010) |
| "Total duration of arrhythmia (seconds) after I/R injury was similar in TGR and SD rats (433 +/- 109 vs." | 1.31 | Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression. ( Crijns, HJ; de Boer, RA; Pinto, YM; Suurmeijer, AJ; van Geel, PP; van Gilst, WH; van Veldhuisen, DJ, 2002) |
| "To produce arrhythmia, the left main coronary artery was occluded for 7 min, followed by 7 min of reperfusion and to produce necrosis, the the left main coronary artery was occluded for 30 min, followed by 120 min of reperfusion." | 1.31 | Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats. ( Acet, A; Birincioglu, M; Ozer, MK; Sahna, E, 2002) |
| "The incidence of ventricular tachyarrhythmias during reperfusion was lower in the losartan group than in the control group (4/15 vs 6/15)." | 1.30 | Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs. ( Annoura, M; Arakawa, K; Handa, K; Hiroki, T; Kumagai, K; Matsuo, K; Nakashima, Y; Yamanouchi, Y, 1997) |
| "Bradykinin acts as an endogenous cardioprotective substance because it suppresses ventricular dysrhythmias induced by ischemia." | 1.30 | Attenuation of epinephrine-induced dysrhythmias by bradykinin: role of nitric oxide and prostaglandins. ( Bolla, BS; de Guzman, FQ; Hussain, Y; Igić, R; Montiague, RR; Rabito, SF; Rajani, V, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (29.17) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mah, DY | 1 |
| Sleeper, LA | 1 |
| Crosson, JE | 1 |
| Czosek, RJ | 1 |
| Love, BA | 1 |
| McCrindle, BW | 1 |
| Muiño-Mosquera, L | 1 |
| Olson, AK | 1 |
| Pilcher, TA | 1 |
| Tierney, ESS | 1 |
| Shah, MJ | 1 |
| Wechsler, SB | 1 |
| Young, LT | 1 |
| Lacro, RV | 1 |
| Chiale, PA | 1 |
| Etcheverry, D | 1 |
| Pastori, JD | 1 |
| Garro, HA | 1 |
| Fernández, PA | 1 |
| González, MD | 1 |
| Elizari, MV | 1 |
| Bozbaş, SS | 1 |
| Bozbaş, H | 1 |
| Atar, A | 1 |
| Ulubay, G | 1 |
| Oner Eyüboğlu, F | 1 |
| Stein, M | 1 |
| Boulaksil, M | 1 |
| Jansen, JA | 1 |
| Herold, E | 1 |
| Noorman, M | 1 |
| Joles, JA | 1 |
| van Veen, TA | 1 |
| Houtman, MJ | 1 |
| Engelen, MA | 1 |
| Hauer, RN | 1 |
| de Bakker, JM | 1 |
| van Rijen, HV | 1 |
| Wachtell, K | 2 |
| Gerdts, E | 1 |
| Aurigemma, GP | 1 |
| Boman, K | 1 |
| Dahlöf, B | 3 |
| Nieminen, MS | 1 |
| Olsen, MH | 2 |
| Okin, PM | 2 |
| Palmieri, V | 1 |
| Rokkedal, JE | 1 |
| Devereux, RB | 2 |
| Kjeldsen, SE | 1 |
| Julius, S | 1 |
| Hille, DA | 1 |
| Edelman, JM | 2 |
| Safari, F | 1 |
| Hajizadeh, S | 1 |
| Shekarforoush, S | 1 |
| Bayat, G | 1 |
| Foadoddini, M | 1 |
| Khoshbaten, A | 1 |
| Oudot, A | 1 |
| Vergely, C | 1 |
| Ecarnot-Laubriet, A | 1 |
| Rochette, L | 1 |
| Lindholm, LH | 1 |
| Ibsen, H | 1 |
| Borch-Johnsen, K | 1 |
| Snapinn, S | 1 |
| Diener, HC | 1 |
| Pourdjabbar, A | 1 |
| Parker, TG | 1 |
| Desjardins, JF | 1 |
| Nguyen, QT | 1 |
| Tsoporis, JN | 1 |
| Lapointe, N | 1 |
| Rouleau, JL | 1 |
| Wang, YH | 1 |
| Shi, CX | 1 |
| Dong, F | 1 |
| Sheng, JW | 1 |
| Xu, YF | 1 |
| Matsuo, K | 1 |
| Kumagai, K | 1 |
| Annoura, M | 1 |
| Yamanouchi, Y | 1 |
| Handa, K | 1 |
| Nakashima, Y | 1 |
| Hiroki, T | 1 |
| Arakawa, K | 1 |
| Lee, YM | 1 |
| Peng, YY | 1 |
| Ding, YA | 1 |
| Yen, MH | 1 |
| Rajani, V | 1 |
| Hussain, Y | 1 |
| Bolla, BS | 1 |
| de Guzman, FQ | 1 |
| Montiague, RR | 1 |
| Igić, R | 1 |
| Rabito, SF | 1 |
| Hunyady, L | 1 |
| Nagy, L | 1 |
| Peczkowska, M | 1 |
| Kabat, M | 1 |
| Janaszek-Sitkowska, H | 1 |
| Lynch, JJ | 1 |
| Stump, GL | 1 |
| Wallace, AA | 1 |
| Painter, CA | 1 |
| Thomas, JM | 1 |
| Kusma, SE | 1 |
| Gould, RJ | 1 |
| Grossman, W | 1 |
| Gavras, I | 1 |
| Gavras, H | 1 |
| Zhu, B | 1 |
| Sun, Y | 1 |
| Sievers, RE | 2 |
| Browne, AE | 2 |
| Lee, RJ | 2 |
| Chatterjee, K | 2 |
| Parmley, WW | 2 |
| de Boer, RA | 1 |
| van Geel, PP | 1 |
| Pinto, YM | 1 |
| Suurmeijer, AJ | 1 |
| Crijns, HJ | 1 |
| van Gilst, WH | 1 |
| van Veldhuisen, DJ | 1 |
| Zhu, BQ | 1 |
| Hillman, RT | 1 |
| Chair, K | 1 |
| Glantz, SA | 1 |
| Ozer, MK | 1 |
| Sahna, E | 1 |
| Birincioglu, M | 1 |
| Acet, A | 1 |
| Fleetwood, G | 1 |
| Boutinet, S | 1 |
| Meier, M | 1 |
| Wood, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for losartan and Arrhythmias, Cardiac
| Article | Year |
|---|---|
[AT1 angiotensin receptor inhibition as a new therapeutic possibility].
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1997 |
[New therapeutic perspectives associated with the introduction of angiotensin II receptor antagonists].
Topics: Aged; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Cardiovascular Diseases; Clinical Tria | 1997 |
The antiarrhythmic potential of angiotensin II antagonism: experience with losartan.
Topics: Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardi | 2000 |
3 trials available for losartan and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Comparative effects of losartan and nifedipine therapy on exercise capacity, Doppler echocardiographic parameters and endothelin levels in patients with secondary pulmonary hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Diastol | 2010 |
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Cardiovascular Diseases; Cause of Dea | 2010 |
[AT1 angiotensin receptor inhibition as a new therapeutic possibility].
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1997 |
19 other studies available for losartan and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Arrhythmias | 2018 |
Clinical evaluation of losartan and diltiazem on the development of T-wave memory by right apical ventricular pacing.
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardi | 2014 |
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr | 2010 |
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; | 2010 |
Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Heart; Heart Rate | 2012 |
Angiotensin II activates NADPH oxidase in isolated rat hearts subjected to ischaemia-reperfusion.
Topics: Angiotensin II; Animals; Arrhythmias, Cardiac; Coronary Circulation; Enzyme Activation; Heart; In Vi | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: reduced ventricular arrhythmias and improved survival.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pressure; Gene Express | 2005 |
Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor.
Topics: Action Potentials; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Ca | 2008 |
Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac | 1997 |
Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats.
Topics: Acute Disease; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Ar | 1997 |
Attenuation of epinephrine-induced dysrhythmias by bradykinin: role of nitric oxide and prostaglandins.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Car | 1997 |
EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction.
Topics: Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhyt | 1999 |
Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Disease Mode | 2001 |
Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression.
Topics: Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Anti-Arrhythmia Agents; Ar | 2002 |
The renin-angiotensin system does not contribute to the endothelial dysfunction and increased infarct size in rats exposed to second hand smoke.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Electrocardiography; Endothe | 2002 |
Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia | 2002 |
Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart.
Topics: Animals; Arrhythmias, Cardiac; Creatine Kinase; Enalaprilat; Imidazoles; In Vitro Techniques; Losart | 1991 |